Physician profile
Kalgi Modi
NPI 1316957889
$3,910.11
in general payments reported to CMS, 2019-2025
25 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $174 · 2021: $337 · 2022: $666 · 2023: $359 · 2024: $562 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332 · Travel and Lodging: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.92 |
| Travel and Lodging | $916.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,044.48 | 2024-2025 | General - Therapies, Avvigo Guidance System, General - Ep |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $487.82 | 2019-2025 | Lifevest |
| Abiomed | $455.51 | 2022-2025 | Impella |
| Astrazeneca Pharmaceuticals Lp | $252.43 | 2019-2025 | Lokelma |
| E.R. Squibb & Sons, L.L.C. | $227.75 | 2019-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $226.57 | 2021-2024 | |
| Shockwave Medical, INC | $187.65 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $180.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $177.03 | 2019-2021 | |
| Pfizer INC. | $136.18 | 2019-2024 | |
| Abbott Laboratories | $93.08 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $84.54 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $49.82 | 2022 | |
| Daiichi Sankyo INC. | $49.36 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.10 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $39.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.11 | 2025 | |
| Cardiovascular Systems INC. | $22.21 | 2023 | Diamondback Coronary |
| Asahi Intecc USA, INC. | $20.99 | 2024 | Peripheral Vascular |
| Actelion Pharmaceuticals US, INC. | $19.13 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.35 | 2024 | |
| Elutia, INC. | $18.06 | 2023 | |
| Cmp Pharma, INC. | $17.41 | 2022 | |
| Medtronic, INC. | $16.84 | 2024 | Corevalve Evolut R |
| Amgen INC. | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalgi Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.